BioCryst Pharmaceuticals, Inc.
Financials
Valuation Metrics
BioCryst Pharmaceuticals, Inc.'s Market Cap is $2.21B. At end of 2025 it was $1.65B. Ranked #1952 of 3,121 in US market (top 63%), #738 of 1,463 on NASDAQ (top 50%), #127 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.21B | US#1,952/3,121 Sec#127/266 |
| Revenue | $941M | US#1,914/3,121 Sec#55/266 |
| Net Income | $-385M | US—/3,121 Sec—/266 |
| Total Assets | $558M | US#2,730/3,121 Sec#152/266 |
| Net Assets | $-454M | US#3,017/3,121 Sec#264/266 |
| Employees | 435 | US#2,317/3,121 Sec#86/266 |
| Value | ||
| P/S | 2.35x | US#1,441/3,121 Sec#35/266 |
| FCF Yield | 16.15% | US#237/3,121 Sec#8/266 |
| Profitability | ||
| ROA | -68.96% | US#3,032/3,121 Sec#238/266 |
| Op. Margin | -33.29% | US#2,648/3,121 Sec#105/266 |
| Revenue Growth | 68.72% | US#154/3,121 Sec#41/266 |
| Financial Health | ||
| Total Debt | $410M | US#1,977/3,121 Sec#70/266 |
| FCF | $357M | US#1,060/3,121 Sec#37/266 |
| Cash | $155M | US#1,940/3,121 Sec#133/266 |
| Current Ratio | 2.32x | US#1,076/3,121 Sec#212/266 |
| Performance | ||
| 1Y Return | 12.99% | US#1,377/3,121 Sec#167/266 |
| 1M Return | -10.31% | US#2,469/3,121 Sec#189/266 |
| From 52W High | -22.46% | US#1,651/3,121 Sec#124/266 |
| 1Y MDD | -26.91% | US#1,181/3,121 Sec#67/266 |
| Trading | ||
| Volume | 4,583,645 shares | US#367/3,121 Sec#30/266 |
| Trading Value | $40M | US#1,424/3,121 Sec#111/266 |
| Per Share | ||
| EPS | $-1.51 | US—/3,121 Sec—/266 |
| BPS | $-1.79 | US—/3,121 Sec—/266 |
Company Info
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.